Lila Adnane
Publications by Year
Research Areas
Enzyme function and inhibition, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Chemical Synthesis and Analysis, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis(2004)4,006 cited
- → Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling(2008)1,428 cited
- → Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity(2010)1,313 cited
- → Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature(2006)465 cited
- → Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9(2011)66 cited
- → Recent Advances in the Research and Development of RAF Kinase Inhibitors(2006)48 cited
- Preclinical characterization of BAY 73-4506: A kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases(2007)
- → AI-Enhanced ECG diagnosis system for acute myocardial infarction with LBBB: Constant-Q transform and ResNet-50 integration(2024)1 cited
- → Data from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9(2023)
- → Supplementary Figure 4 from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9(2023)